Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients.

ABSTRACT:

Background

The measurement of ESR1 and PIK3CA mutations in plasma cell-free DNA (cfDNA) has been studied as a non-invasive method to quickly assess and monitor endocrine therapy (ET) resistant metastatic breast cancer (MBC) patients.

Methods

The subjects of this retrospective study were a total of 185 plasma samples from 86 estrogen receptor-positive BC patients, of which 151 plasma samples were from 69 MBC patients and 34 plasma samples were from 17 primary BC (PBC) patients. We developed multiplex droplet digital PCR assays to verify the clinical significance of ESR1 and PIK3CA mutations both in a snapshot and serially in these patients.

Results

cfDNA ESR1 and PIK3CA mutations were found in 28.9% and 24.6 % of MBC patients,

SUBMITTER: Takeshita T 

PROVIDER: S-EPMC5581019 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature